IPO Roundup: Implant producer TELA Bio starts strong, two Chinese companies stumble out of the gate

The soft tissue implant producer raised $52 million in its IPO after offering 4 million shares at $13 each

Gold IPO key on a keyboard
ECMOHO, a Shanghai wellness retailer, and 36KR, a Beijing media publisher, each saw shares dip in the first day of trading

TELA Bio Inc (NASDAQ:TELA), a producer of soft tissue reconstruction implants, raised $52 million in its IPO after offering 4 million shares at $13 each, which was below its projected range of $14 to $16. 

The company, based in Malvern, Pennsylvania, offers reinforcing implants used in hernia repair, abdominal wall reconstruction, as well as plastic and reconstructive surgery. Its products have been used in more than 6,500 patients, the company said.

Shares opened at $13.91 and rose to $15, more than 15% above its IPO price.

READ: IPO Roundup: Three new companies make public debuts; Canada's largest IPO ever gets canned

ECMOHO Ltd (NASDAQ:MOHO), an online health and wellness retailer based in Shanghai, raised $44 million by offering 4.4 million shares at $10 per share, the low end of its $10 to $12 range. 

The seven-year-old company bills itself as a provider of personalized health supplements, food, personal care products, household healthcare equipment and more. ECMOHO was China’s top non-medical health and wellness integrated solution industry in terms of revenue in 2018 with a market share of 2.6%, according to Frost & Sullivan.

ECMOHO stock debuted at $10.10 and slid to $9.99, 0.1% below its IPO price.

36KR Holdings Inc (NASDAQ:KRKR), a Chinese online media publisher, completed a $20 million downsized IPO. 

The company offered 1.4 million shares — 2.2 million fewer than originally planned — at $14.50 per share, the low end of its $14.50 to $17.50 range. 

The Beijing-based company bills itself a top coverage provider of so-called new economy content and has expanded to provide business offerings such as online advertising services, enterprise value-added services and subscription services.

The company claims to be the first to cover ByteDance, the Chinese company behind TikTok, back in January 2013.

36KR opened trading at $12.58 and dipped to $13.90, 4.1% lower than its IPO price.

CNS Pharmaceuticals Inc (NASDAQ:CNSP), a Houston biotechnology company focused on brain cancer therapies, raised $9 million after offering 2.1 million shares and pricing at the low end of its estimated $4 to $5 range. 

The company, originally scheduled to go public last week, is developing drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its lead drug candidate, Berubicin, is designed to treat glioblastoma, a type of brain cancer currently considered to be incurable.

Shares started trading at $4.11 and climbed to $4.40, 10% above its IPO price.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com 

Follow him on Twitter @andrew_kessel

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Tiziana Life Sciences: Delivery method & data 'looks promising' ahead of...

Tiziana Life Sciences PLC (LON:TILS)(NASDAQ:TLSA) has announced plans to begin a clinical study of its nasally administered Foralumab in COVID-19 patients in Brazil. Proactive analyst Emma Ulker talks to Katie Pilbeam about the trial which will begin shortly with clinical data potentially...

2 hours, 9 minutes ago

2 min read